Encysive agrees to work with FDA on Thelin study

HOUSTON Encysive Pharmaceuticals is planning on moving its hypertension drug candidate Thelin into a late-stage study, according to the Associated Press.

The drug, indicated for hypertension, has been repeatedly denied approval by the Food and Drug Administration. The agency has sent three letters of request for more information from the company since they first applied for approval in 2005. The FDA wants the company to conduct a new study before it would be considered for approval.

The company has said it will work with the FDA to finish a protocol for the Phase III clinical trial.